Investors Key Financial data Per Share Data Per Share Data € 2016 2017 2018 2019 2020 Earnings per share (EPS) 1.152 1.395 1.529 1.8 1.725 Shareholders'equity per share 4.40 4.93 4.72 5.825 6.187 Dividend for share 0.7 0.85 0.92 1.00 1.05 Annual Report Corporate Brochure The Prize Alert Service Italiano | English Company data RECORDATI S.p.A. VIA M. CIVITALI, 1 - 20148 MILAN, ITALY SHARE CAPITAL € 26.140.644,5 i.v. REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150 CODICE FISCALE/P. IVA 00748210150 R.E.A. MILANO 401832 Company subject to the Management and Coordination Activities of Rossini Luxembourg S.àr.l delivered by Tech Style Site Services Alert Services Legal Notice Privacy Policy Latest News 29 October 2021 RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS 28 October 2021 RECORDATI: 2021 FIRST NINE MONTHS RESULTS APPROVED. REVENUE +5.7%, EBITDA +2.1% AND NET INCOME +8.1%. THE RECOVERY BEGUN IN THE SECOND QUARTER CONTINUES

About Us Our Mission Recordati is an international specialty pharmaceutical group dedicated to partnering, discovering and developing innovative, value-added products that improve the quality of life and help people to enjoy longer, healthier and more productive lives. Our success as a healthcare enterprise will benefit not only the patients whose needs we meet but all our stakeholders whom we serve – our customers, our shareholders, our employees and their families Annual Report Corporate Brochure The Prize Alert Service Italiano | English Company data RECORDATI S.p.A. VIA M. CIVITALI, 1 - 20148 MILAN, ITALY SHARE CAPITAL € 26.140.644,5 i.v. REG. IMP. MILANO, MONZA, BRIANZA e LODI 00748210150 CODICE FISCALE/P. IVA 00748210150 R.E.A. MILANO 401832 Company subject to the Management and Coordination Activities of Rossini Luxembourg S.àr.l delivered by Tech Style Site Services Alert Services Legal Notice Privacy Policy Latest News 29 October 2021 RECORDATI: SHARE BUY-BACK PROGRAM TO SERVICE THE STOCK OPTION PLANS 28 October 2021 RECORDATI: 2021 FIRST NINE MONTHS RESULTS APPROVED. REVENUE +5.7%, EBITDA +2.1% AND NET INCOME +8.1%. THE RECOVERY BEGUN IN THE SECOND QUARTER CONTINUES